Best Brain MRI doctors in Turkey: TOP 144 doctors

Specialist of regenerative medicine

Dr. Başak Bolluk Kılıç, MD, is a neurologist with expertise in Parkinson’s disease and other movement disorders. She is skilled in EEG, EMG, Botulinum Toxin treatments, and Deep Brain Stimulation (DBS) programming. Dr. Kılıç received advanced training in Turkey and abroad.

She practices at Istanbul Medipol University PARMER. Dr. Kılıç offers personalized and evidence-based care for patients with movement disorders. She is known for her dedication to improving patient outcomes through advanced therapies and specialized treatment plans.

Dr Önul is FROM THE BEST DOCTORS in the field of Endoscopic skull base surgery and pituitary surgery Brain tumor surgery (Neuro Oncological surgery)


I was born in Artvin in 1977. He became a doctor from KTU Faculty of Medicine in 2001, and Bakırköy Prof. Dr. I became a Neurosurgery Specialist by getting the title of specialist from Mazhar Osman Mental Health and Neurological Diseases Training and Research Hospital. Again, in the same hospital, I was entitled to the title of associate professor in 2016. I continue to work at Başakşehir Çam and Sakura City Hospital, where I voluntarily joined with the task of establishing the Neurosurgery Clinic with my teammates. I am married and have 2 children. I love painting. I am very interested in children's literature. I have 10 printed children's tales

Education and Expertise

GATA Military Medical Faculty

GATA Haydarpaşa Training Hospital Neurosurgery Clinic (Specialization)

Beykent University Hospital and Health Institutions Management (Master's)

Experience

GATA Military Medical Faculty Trainee Doctor (6 months)

Samsun Sahara Medical School Comm. (3 months)

Naval Command War Squadron TCG Diligence Medical Officer (2 years)

Dz.K.K. Submarine Battery Factory Infirmary Doctor (3 months)

Naval Forces Command Infirmary Doctor (3 months)

GATA Haydarpaşa Training Hospital Chief Assistant (12 years)

Kasımpaşa Marine Hospital Neurosurgery Clinic Chief (5 years)

Bahçelievler Medical Park Hospital Neurosurgery Specialist (11 years)

Altınbaş University Faculty of Medicine Neurosurgery Lecturer. Member (4 years)

Altınbaş University Faculty of Medicine Head of Neurosurgery Department. (3 years)

Basic and Advanced Cardiac life support courses (BASIC)

Basic and Advanced Cardiac life support courses (ADVANCED)

GATA Military Medical Faculty. Microsurgery Training Course

Istanbul Vatan Hospital Hand surgery microsurgery course

Neuroanatomy course

Spine Surgery course

Professional Memberships

Turkish Neurosurgery Association

Spine Society of Europe

Turkish Spinal and Peripheral Nerve Surgery Group

Assoc. Prof.  Nesrin Helvacı Yılmaz graduated from Hacettepe University in 2000 as a Medical Doctor.  She completed her specialty training in the Department of Neurology at Ankara University in 2006.

She started her compulsory service in Mardin Nusaybin State Hospital in 2007.  Nesrin Helvacı Yılmaz continued her duty in Gaziantep 27 December State Hospital in 2008.  She worked as a neurologist at Biophysis Nilüfer Medical Center and Ali Osman Sönmez Oncology Hospital in Bursa between 2010-2011, and at Istanbul Universal Aksaray Hospital between 2011-2012. From October 2012, she started to work as a Doctor Lecturer in Istanbul Medipol University Neurology Department.  Nesrin Helvacı Yılmaz received the title of associate professor in 2021.  In 2015, she worked as an Honorary Observer in Parkinson's Disease and Deep Brain Stimulation (Neuromodulation) at UCL Queen Square Institute of Neurology, National Hospital for Neurology in London.  She took part in many training programs on Deep Brain Stimulation (Neuromodulation) in Turkey and abroad between 2013-2022.

Regarding her speciality in Parkinson's disease and movement disorders, she has 5 Tubitak projects, a 2-chapter book , 30 clinical researches and 80 reports presented in domestic and abroad. Assoc. Prof. Nesrin Helvacı Yılmaz, who is still working within the staff of Medipol University, managed the Parkinson's and Movement Disorders Unit of the Department of Neurology during her working time and plans Deep Brain Stimulation therapy applications with the neurosurgical team.

Since September 2018, she has been working as a coordinator for student education in the 5th semester of Neurology. As of December 2022, she has developed treatment plans for patients at Medipol University Istanbul Parkinson's Disease and Movement Disorders Center (PARMER) and provides the most appropriate personal medical follow-up and treatment support for each patient.

PUBLICATIONS

1-Yilmaz N, Yigit A, Akbostanci MC. Clozapine induced epilepsy. Revue Neurologique 2004, Nov;160/11:1093.

2-Nesrin Helvacı Yılmaz, Nursel Aydın. Sıcak Su Epilepsili Bir Olgu. Türkiye Klinikleri Nöroloji Dergisi 2004/Cilt2/Sayı 2.

3-Nesrin Helvacı Yılmaz, Nursel Aydın. Refleks Epilepsiler. Türkiye Klinikleri Nöroloji Dergisi 2004/Cilt2/Sayı 2.

4-Mine Hayriye Sorgun, Bilge Koçer, Funda Kaplan, Nesrin Yılmaz, Nezih Yücemen, Canan Yücesan. Multipl Sklerozda Kraniyal Nöropati. Turk Norol Derg 2011;17:137-142.

5-Nesrin Helvacı Yılmaz, Gökçen Duymaz, Mehmet Akif Yaşar. Parkinson Hastalığı Olan Bir Olguda Malign Sendrom. Turk Norol Derg 2012:18;123-125.

6-Yilmaz NH, Akbostanci MC, Oto A, Aykac O. Prevalence of restless legs syndrome in Ankara, Turkey: an analysis of diagnostic criteria and awareness. Acta Neurol Belg 2012 Oct 31. [Epub ahead of print].

7-Yılmaz NH, Bingol AP. Sensitivity and specificity of Ankara University Cerebral Dominance Inventory in comparison with the Wada test. Acta Neurol Belg 2013 Jun 6 [Epub ahead of print].

8-Sema Demirci, Nesrin Helvacı Yılmaz, Efsun Şenocak, Fatih Han Bölükbaşı. Pons Kavernomu: Kranial Manyetik Rezonans Görüntüleme Bulguları. Turk Norol Derg 2012:19:72.

9-Nesrin Helvacı Yılmaz, Sinem Atik Güngör, Taflan Sahlepçi. Küçük hücreli akciğer kanseri tedavisinde cisplatin kullanımı sırasında gelişen akut iskemik inme: olgu sunumu. J Kartal TR. Baskıdaki Makaleler: KEAH-26937.

POSTERLER:

-Serebral venöz tromboz ve bruselloz Birlikteliği; Olgu Sunumu (42. Ulusal Nöroloji Kongresi-Antalya 2006)

-Waldenström makroglobulinemisine eşlik eden epileptik nöbetler ve nonkonvülsif status epileptikus (42. Ulusal Nöroloji Kongresi-Antalya 2006)

-Prevalence of Restless Legs Syndrome in Ankara, Turkey (16. Uluslararası Parkinson ve Hareket Bozuklukları Kongresi-Dublin 2012).

-Konjenital Miyastenik Sendrom (29. Ulusal Nörofizyoloji EEG-EMG Kongresi- Antalya 2013).

-Beşinci haftada duyusal iletimleri normal olan bir enjeksiyon nöropatisi olgusu (29. Ulusal Nörofizyoloji EEG-EMG Kongresi- Antalya 2013).

-Olgu sunumu: Mononöritis mültipleks ve lepra (29. Ulusal Nörofizyoloji EEG-EMG Kongresi- Antalya 2013).

-İdyopatik Parkinson Hastalığı’nda hızlanmış unutma ve uyku kalitesi (10. Ulusal Parkinson ve Hareket Bozuklukları Kongresi-Antalya 2013).

-Hiperglisemiye bağlı hemikore ve bazal gangliyon hiperintensitesi: Olgu sunumu (10. Ulusal Parkinson ve Hareket Bozuklukları Kongresi-Antalya 2013).

Dr. Gulsen Kose is a respected pediatric neurologist with over 40 years of experience. She played a key role in developing pediatric neurology in Turkey. In 1993, she helped establish the Pediatric Neurology Department at Ankara Pediatric Health and Hematology Oncology Hospital. Her work set new standards for patient care.

Dr. Kose focuses on neurodegenerative, neurometabolic, and rare acquired neurological diseases. She has special expertise in Autoimmune Encephalitis and SSPE. She is also known for her work with epilepsy, febrile seizures, and cerebral palsy. Her care has improved the lives of thousands of children.

Dr. Kose is a founding member of the Turkish Society of Developmental Pediatric Neurology. She is also active in five major international pediatric neurology societies. As a clinic chief and associate professor, she has influenced clinical protocols and specialist training across the country.

Education and Specialization

• Bachelor’s Degree: Çukurova University Faculty of Medicine (1987/1993)
• Medical Specialization: Department of Pediatrics, Fırat University (1993/2001)
• Subspecialty: Pediatric Neurology Unit, Hacettepe University (2002/2004)

Professional Experience

• General Practitioner: Mardin State Hospital, Emergency Department (1993/1996)
• Research Assistant: Faculty of Medicine, Fırat University (1996/2001)
• Lecturer: Faculty of Medicine, İnönü University (2001/2002)
• Subspecialty Research Assistant: Faculty of Medicine, Hacettepe University (2002/2004)
• Assistant Professor: Faculty of Medicine, İnönü University (2004/2008)
• Associate Professor: Faculty of Medicine, İnönü University (2008/2014)
• Professor: Faculty of Medicine, İnönü University (2014/2023)

Dr. Hilmi Apak is a respected pediatric hematology-oncology specialist with more than 21 years of experience. He is trained in pediatric oncology. Dr. Apak has led advanced treatments, including bone marrow transplantation, leukemia chemotherapy, and CAR T-cell therapy.

He has published 75 international medical articles, showing his strong contribution to pediatric oncology research. Dr. Apak has worked as assistant editor for the Turkish Pediatrics Archives Periodical. He has also held important academic and leadership positions, such as Head of Pediatric Hematology-Oncology at Istanbul University-Cerrahpaşa.

Associate Professor Dr. Yusuf AÇIKGÖZ
Specialization: Medical Oncology

Education:

• 2004-2011: İnönü University Faculty of Medicine
• 2011-2016: Ankara Numune Training and Research Hospital, Internal Medicine
• 2017-2022: Health Sciences University, Medical Oncology

Professional Experience:

• 2016-2017: Bingöl City Hospital, Internal Medicine
• 2021-2022: Health Sciences University, Medical Oncology
• 2022-2023: Kastamonu Education and Research Hospital, Medical Oncology
• 2023-2024: Ohio State University, Medical Oncology
• 2024-Present: Lokman Hekim University, Medical Oncology, Ankara Hospital

Clinical Trials, Courses, Certifications:

Clinical Trials:

• 2017-2021: Phase III, CheckMate-649 Study (Assistant Investigator)
• 2022-Present: Phase III, Fortitude-101 Study (Assistant Investigator)

Courses:

• 2018: Medicres Basic and Advanced Biostatistics Training Program (ongoing), Istanbul-Vienna
• 2019: Immuno-Oncology Education Course, March 1-2, 2019, Vienna, Central European Cooperative Oncology Group (CECOG)
• 2018: Good Clinical Practice Certification, April 7-8, 2018, Ankara, Health Sciences University
• 2017: Basic Oncology Training Program, November 25-26, 2017, Adana, Clinical Oncology Society
• 2016: Basic Ultrasonography Course (10 hours theoretical + 10 hours practical), September 24-25, 2016, Ankara, Turkish Emergency Medicine Association

Certifications:

• Ongoing: ECFMG Certification
• 2024: CITI Responsible Conduct of Research (The Ohio State University)
• 2024: CITI IACUC-Laboratory Animal Research (The Ohio State University)
• 2024: CITI Human Subjects Protection (The Ohio State University)
• 2024: CITI Good Clinical Practice (The Ohio State University)
• 2023: Occupational English Test (OET)
• 2019: International English Language Testing System (IELTS), Total Score: 6.5, May 26, 2019, Ankara, British Council
• 2017: USMLE Step 2 CK Exam; Score: 244, February 7, 2017
• 2016: USMLE Step 1 Exam; Score: 215, August 25, 2016

Memberships:

• American Society of Clinical Oncology (ASCO) - 2022
• Turkish Society of Medical Oncology - 2020

EDUCATION:

2015

Uludag University, Ophthalmology

2008

Eskisehir Osmangazi University, Faculty of Medicine

2001

Kırıkkale Science High School, Numerical

EXPERIENCE:

2019 Gazi University Faculty of Medicine Ophthalmology (Vitreo-Retinal Surgery and Medical Retina Fellowship)

2016 SBÜ Zekai Tahir Burak EAH (Retinopathy of Prematurity Fellowship)/

2015 - 2023 Kocaeli Derince Training and Research Hospital

2023 - Medipol University Pendik Hospital

Education and Specialization

• 2006: Kocaeli University Faculty of Medicine
• 2014: Akdeniz University Faculty of Medicine, Internal Medicine
• 2018: Akdeniz University Faculty of Medicine, Medical Oncology

Experience

• 2006 - 2008: Konya Derebucak District Hospital
• 2009 - 2015: Akdeniz University Hospital
• 2015: Antalya Kaş State Hospital
• 2015 - 2016: İnönü University Faculty of Medicine
• 2016 - 2021: Akdeniz University Hospital
• 2021 - 2023: Antalya Training and Research Hospital

PROFESSIONAL EXPERIENCE

2011-2012
Erzurum Koprukoyu State Hospital
Department: General Medicine

2012-2017
Istanbul University Cerrahpaşa Medical Faculty
Department: Internal Medicine

06/2017-10/2017
Istanbul Gaziosmanpasa Taksim Training and Research Hospital
Department: Internal Medicine

10/2017-11/2018
Istanbul University Istanbul Medical Faculty
Department: Allergy and Immunology Fellowship

2018/2022
Istanbul University Oncology Institute
Department: Medical Oncology Fellowship

2022-2023
Tekirdag City Hospital
Department: Medical Oncology Specialist

2023-present
Istanbul Medipol University Medipol Bahcelievler Private Hospital
Department: Medical Oncology Assoc. Prof.

EDUCATION

2005-2011
Medical Education
Sivas Cumhuriyet University Medical Faculty, Sivas, Turkey

2012-2017
Internal Medicine
Istanbul University Cerrahpaşa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey

2017-2018
Allergy-Immunology Fellowship
Istanbul University Istanbul Medical Faculty
Department of Internal Medicine, Division of Allergy and Immunology, Istanbul, Turkey

2018-2022
Medical Oncology Fellowship
Istanbul University Oncology Institute, Department of Medical Oncology, Istanbul, Turkey

2022
ESMO Board Certification in Medical Oncology
10th September 2022 in Paris, France.

2023
Medical Oncology Assoc. Prof.
Istanbul Medipol University Department of Medical Oncology, Istanbul, Turkey

INTERNATIONAL CLINICAL TRIALS:

1. Astefania - ROCHE

• Title: A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
• Role: Subinvestigator

2. PFİZER

• Title: A Study Of Lorlatinib Versus Crizotinib In First-Line Treatment Of Patients With ALK-Positive NSCLC
• Role: Subinvestigator

3. RECITE - AMGEN

• Title: Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer
• Role: Subinvestigator

4. NAVIGATE - BAYER

• Title: A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors
• Role: Subinvestigator

5. RUBY - Tesaro (PRA)

• Title: A Phase 3, Randomized, Double-blind, Multicenter Study of Dostarlimab (TSR-042) Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Patients With Recurrent or Primary Advanced Endometrial Cancer
• Role: Subinvestigator

6. ENGOT-ov43/GOG-3036 - MSD

• Title: Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK001/ENGOT-ov43/GOG-3036)
• Role: Subinvestigator

7. ASTRA ZENECA

• Title: To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.
• Role: Subinvestigator

8. ROSY-O - ASTRA ZENECA

• Title: Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
• Role: Subinvestigator
•  

INTERNATIONAL PUBLICATIONS

I. Published journal articles indexed by SCI, SSCI, and AHCI

Weekly Paclitaxel in Classic Kaposi Sarcoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Ahmed, M. A., Karaman, S., & Aydiner, A.
• Journal: Medicine, 102(5)

Carboplatin Desensitization in Ovarian Carcinoma

• Authors: Paksoy, N., Khanmammadov, N., Doğan, İ., Ferhatoğlu, F., Yildiz, A., Ak, N., & Aydiner, A.
• Journal: Medicine, 101(45), e31726

High-Dose Chemotherapy for Ewing’s Sarcoma

• Authors: Paksoy, N., Ferhatoglu, F., Dogan, İ., Khanmammadov, N., Celik, A. I., Gulbas, Z., & Başaran, M.
• Journal: Medicine, 101(49), e32213

Multidrug Refractory TFE3(+) Renal Cell Carcinoma

• Authors: Paksoy, Nail, et al.
• Journal: Journal of Oncology Pharmacy Practice, 2022, 28.1: 215-221

Crizotinib Efficacy in NSCLC with MET Alterations

• Authors: Gürbüz, M., Kiliçkap, S., Bilici, A., Karadurmuş, N., Sezer, A., Şendur, M. A. N., ... & Demirkazik, A.
• Journal: Medicine, 101(50), e32368

Clinicopathological Features in ALK Mutant NSCLC

• Authors: Dogan, I., Gurbuz, M., Paksoy, N., Ferhatoglu, F., Vatansever, S., Saip, P., ... & Aydiner, A.
• Journal: Medicine, 101(34)

PSMA-Based Tumor Burden in Prostate Cancer

• Authors: HAS SIMSEK, Duygu, et al.
• Journal: Annals of Nuclear Medicine, 2021, 35.6: 680-690

Atezolizumab in Metastatic Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: European Urology Focus, 2021, 7.5: 1061-1066

Pulmonary Sarcomatoid Carcinoma

• Authors: FERHATOGLU, Ferhat, et al.
• Journal: Oncology Research and Treatment, 2021, 44.11: 590-601

Prognostic Factors in Atezolizumab-Treated Urothelial Carcinoma

• Authors: TURAL, Deniz, et al.
• Journal: International Journal of Clinical Oncology, 2021, 26.8: 1506-1513

Atezolizumab with Chemotherapy in Small Cell Lung Cancer

• Authors: GÜRBÜZ, Mustafa, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 1-9

FOLFIRINOX vs. Gemcitabine + Nab-Paclitaxel in Pancreatic Cancer

• Authors: AY, Seval, et al.
• Journal: Journal of Chemotherapy, 2022, 1-7

Trastuzumab Emtansine in Older HER2-Positive Breast Cancer Patients

• Authors: CIL, Ibrahim, et al.
• Journal: Tumori Journal, 2022, 108.1: 19-25

Real-Life Efficacy of Osimertinib in Advanced NSCLC

• Authors: HIZAL, Mutlu, et al.
• Journal: Journal of Cancer Research and Clinical Oncology, 2022, 148.6: 1501-1508

ALK-Positive Cells Percentage and Alectinib Efficacy

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Atcı, M. M., Kahraman, S., Kılıçkap, S., ... & Şendur, M. A. N.
• Journal: Journal of Cancer Research and Clinical Oncology, 149(8), 4141-4148

Real-World Data on Alectinib in ALK-Positive NSCLC

• Authors: Hizal, M., Bilgin, B., Paksoy, N., Kılıçkap, S., Atcı, M. M., Kahraman, S., ... & Şendur, M. A. N.
• Journal: Future Oncology, 18(23), 2573-2582

Prognostic Factors in Metastatic RCC with T790M Mutation

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Desensitization Protocol in Lenalidomide Hypersensitivity Reactions

• Authors: DEMIR, Semra, et al.
• Journal: Annals of Allergy, Asthma & Immunology, 2019, 123.4: 394-397

Factors Associated with Diagnostic Skin Test Positivity in PPI Hypersensitivity

• Authors: ÖZDEMIR, Seçil Kepil, et al.
• Journal: Allergy, 2019, 74.6: 1187-1190

Efficacy of Capecitabine and Temozolomide in Neuroendocrine Tumors

• Authors: Ünal, Ç., Azizy, A., Karabulut, S., Taştekin, D., Akyıldız, A., Yaşar, S., ... & Sağlam, S.
• Journal: The Oncologist, oyad257

Subsequent Treatments in Hormone-Positive Breast Cancer Progression

• Authors: Karacin, C., Oksuzoglu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F., ... & Hacıbekiroğlu, İ.
• Journal: BMC cancer, 23(1), 192

Termination of Trastuzumab in HER2-Positive Metastatic Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Saip, P., & Aydiner, A.
• Journal: Scientific Reports, 13(1), 8779

Long-term Outcomes and Predictors of Recurrence in Node-Negative Early Stage Breast Cancer

• Authors: Dogan, I., Aydin, E., Khanmammadov, N., Paksoy, N., Ferhatoğlu, F., Ak, N., ... & Aydiner, A.
• Journal: Journal of Cancer Research and Clinical Oncology, 1-9

Prognostic Factors Influencing PFS in HER2-Positive Metastatic Breast Cancer

• Authors: Doğan, İ., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydıner, A.
• Journal: European Journal of Breast Health, 19(2), 128

Treatment Efficacy of Ribociclib or Palbociclib plus Letrozole in Metastatic Breast Cancer

• Authors: Kahraman, S., Erul, E., Seyyar, M., Gumusay, O., Bayram, E., Demirel, B. C., ... & Nahit Sendur, M. A.
• Journal: Future Oncology, 19(10), 727-736

Efficacy and Safety of Sorafenib in Adult Metastatic Osteosarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Single-Agent Temozolomide as Salvage Therapy in Heavily Pretreated Metastatic Sarcoma Patients

• Authors: Dogan, I., Paksoy, N., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

Outcomes and Prognostic Factors in Metastatic Renal Cell Carcinoma with Brain Metastases

• Authors: Dogan, I., Iribas, A., Paksoy, N., Vatansever, S., & Basaran, M.
• Journal: Journal of Cancer Research and Therapeutics

FLOT Regimen in First-Line Treatment of Metastatic Gastric Cancer

• Authors: Tastekin, D., Paksoy, N., Dogan, I., Ferhatoglu, F., Khanmammadov, N., Bozbey, H. U., & Karabulut, S.
• Journal: Journal of Cancer Research and Therapeutics

Prognostic Factors of Perioperative FLOT Regimen in Operable Gastric Cancer

• Authors: Erol, C., Sakin, A., Basoglu, T., Ozden, E., Cabuk, D., Dogan, M., ... & Sendur, M. A. N.
• Journal: [Not specified]

Efficacy and Outcomes of Systemic Chemotherapy in Posttransplant Kaposi Sarcoma

• Authors: Khanmammadov, N., Paksoy, N., Doğan, I., Ferhatoğlu, F., Saip, P., & Aydiner, A.
• Journal: Medicine, 102(39), e35383

Comparison of Second-Line Treatments in Metastatic Renal Cell Carcinoma

• Authors: Pehlivan, M., Paksoy, N., Aydin, E., Basaran, M., & Ekenel, M.
• Journal: Medicine, 102(41), e35245

Toxicity Management and Effectiveness of Regorafenib in Advance GIST Patients: A Real-world Study - Authors: Paksoy, N., Ferhatoğlu, F., Doğan, İ., Khanmammadov, N., Bozbey, H. U., Karabulut, S., & Taştekin, D. - Journal: TURKISH JOURNAL OF ONCOLOGY, 1(1)

Demographic and Clinical Features and Factors Associated with Survival in Patients with Primary Glomerulonephritis: Single Tertiary Center Experience - Authors: Paksoy, N., Trabulus, S., Seyahi, N., & Altiparmak, M. R. - Journal: Namik Kemal Tip Dergisi, 11(1)

Efficacy of Sorafenib in Symptomatic Patients with Pretreated Progressive Desmoid Tumors - Authors: Paksoy, N., Ferhatoglu, F., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M.

Nodal Response to Neoadjuvant Chemotherapy is a Better Predictive Factor of Survival Than Miller-Payne Scoring in Breast Cancer - Authors: Ak, Naziye, et al. - Journal: Journal of Oncological Sciences, 7.2: 42-49

Evaluation of Prognostic and Predictive Values of Hemogram Parameters in Patients with Advanced Stage Ovarian Carcinoma - Authors: Ak, Naziye, et al. - Journal: Turkish Journal of Oncology/Türk Onkoloji Dergisi, 2021, 36.4

Identifying Risk Factors Associated with Survival and Drug-Related Toxicities in Imatinib-Resistant Gastrointestinal Stromal Tumor (GIST) Patients Treated with Sunitinib - Authors: Ferhatoglu, F., Karabulut, S., Paksoy, N., & Tastekin, D.

Real-life Outcomes of ROS1 Fusion-positive Metastatic Lung Cancer Patients who were Treated with Crizotinib - Authors: Dogan, İ., Khanmammadov, N., Paksoy, N., Ferhatoglu, F., Aydın, E., Vatansever, S., & Aydine, A. - Journal: TURK ONKOLOJI DERGISI-TURKISH JOURNAL OF ONCOLOGY

Predictors of the acquisition of T790M mutation in EGFR-mutant metastatic lung cancer patients who were treated with EGFR inhibitors - Authors: Dogan, I., Khanmammadov, N., Paksoy, N., Vatansever, S., Saip, P., & Aydıner, A. - Journal: Eurasian Journal of Pulmonology

Laterality of Adrenal Gland Metastasis in Lung Cancer: Results of a Comparative Study - Authors: Ferhatoglu, F., Gagatay, T., Okumus, G., Aydiner, A., Paksoy, N., Ak, N., ... & Saip, P. - Journal: Eurasian Journal of Medical Investigation, 7(2)

Poor Risk Factors Affecting Cancer Patients Infected with Covid-19: A Retrospective Comparative Study from a Pandemic Hospital - Authors: Ferhatoglu, F., Kapağan, T., Paksoy, N., Ak, N., Medetalibeyoğlu, A., Şenkal, N., ... & Vatansever, S. - Journal: Turk Onkoloji Dergisi, 38(1)

Systemic Treatment Outcomes of Progressive Medullary Thyroid Carcinoma from the Registries of a Tertiary Cancer Center - Authors: Ferhatoglu, F., Paksoy, N., & Başaran, M. - Journal: Namik Kemal Tip Dergisi, 10(4)

Evaluation of clinical features and risk factors related to late recurrence (> 5 years) in patients with breast cancer - Authors: Ferhatoglu, F., Aydiner, A., & Paksoy, N. - Journal: Journal of Surgery & Medicine (JOSAM), 6(12)

Assessing the Clinical Impact of Lutetium-177 DOTATATE Peptide Receptor Radionuclide Therapy (PRRT) on Metastatic Neuroendocrine Tumors: A Multicenter Real-World Data from Türkiye

Thesis:

Istanbul University Cerrahpaşa Medical Faculty, Internal Medicine Department PAKSOY, Nail. Demographical, clinical characteristics and survival factors in patients withprimary glomerulonephritis: Cerrahpasa Medical Faculty Experience. (2016)

International Refereed Congress / Symposium Publications in Proceedings (ASCO/ESMO Abstracts)

Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination

• Authors: Dogan, I., Paksoy, N., Ak, N., Vatansever, S., Saip, P., & Aydiner, A. (2022)

Efficacy of regorafenib and 5-fluorouracil-based rechallenge treatment in the third-line treatment of metastatic colorectal cancer: A Turkish oncology group study

• Authors: Şenocak Taşçi, E., Oyan, B., Sonmez, O., Mutlu, A. U., Atcı, M. M., Oner, I., ... & Gulmez, A. (2022)

Long-term outcomes and predictors of recurrence in patients with early-stage node-negative breast cancer

• Authors: Dogan, I., Aydin, E., Paksoy, N., Ferhatoglu, F., Ak, N., Ibis, K., ... & Aydiner, A. (2021)

Efficacy of temozolomide in pretreated patients with metastatic sarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors

• Authors: Ferhatoglu, F., Paksoy, N., Dogan, I., Ak, N., Pehlivan, M., Ekenel, M., & Basaran, M. (2021)

Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma

• Authors: Paksoy, N., Dogan, I., Ekenel, M., & Basaran, M. (2021)

Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases

• Authors: Dogan, İ., Iribas, A., Paksoy, N., Ekenel, M., Vatansever, S., & Basaran, M. (2021)

Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma

• Authors: Tural, D., Olmez, O. F., Sümbül, A. T., Artac, M., Ozhan, N., Akar, E., ... & Erman, M. (2021)

Safety and survival in adult women with platinum-sensitive relapsed BRCA mutant ovarian cancer: A study of patients in Olaparib Turkey Early Access Program—LynTurk study

• Authors: Esin, E., Ahmed, M. A., Yıldırım, H. Ç., Mandel, N. M., Erdemoglu, E., Sari, M., ... & Paydas, S. (2023)

Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experiences

• Authors: Tural, D., Ölmez, Ö. F., Sümbül, A. T., Artaç, M., Özhan, N., Akar, E., ... & Kılıçkap, S. (2021)

EDUCATION:

• Turhan and Mediha Tansel Primary School (1979–1984)
• Kültür College (1984–1988)
• Semiha Şakir High School (1988–1991)
• Marmara University Faculty of Medicine (1991–1997)
• Marmara University Faculty of Medicine, Neurosurgery Department, Specialist Training (1997–2002)
• Title of Associate Professor in Neurosurgery (May 31, 2021)

ADDITIONAL TRAINING:

• "Visiting Physician," University of Southern California, Department of Neurosurgery (1998)
• "Microsurgery Training," GATA (Gülhane Military Medical Academy), Ankara Education and Research Hospital (2003)

PROFESSIONAL EXPERIENCE:

• Gülhane Military Medical Academy Haydarpaşa Training and Research Hospital (2002–2003)
• Dr. Lütfi Kırdar Kartal Training and Research Hospital (2003–2005)
• Private Avicenna Ataşehir Hospital (2005–2012)
• Private 29 Mayıs Hospital (2012–2013)
• Maltepe State Hospital (2013–2018)
• Kartal Dr. Lütfi Kırdar City Hospital (2018–2020)
• Private Academic Hospital (2020–2022)
• Hisar Intercontinental Hospital (2022–2024)
• Private Medipol Acıbadem Regional Hospital (2024–Present)

ADMINISTRATIVE AND ACADEMIC ROLES:

• Board Member, Neurosurgical Society (2006–2009)
• Head of the Emergency Department, Maltepe State Hospital (2014–2016)
• Deputy Chief Physician, Private Academic Hospital (2020–2021)
• Advisory Board Member, Beykent University Faculty of Medicine (2018–2024)
• Faculty Member, Galata University Faculty of Health Sciences (2022–2024)
• Director, Continuous Education Center, Galata University (2022–2024)

My 34 years of medicine – which is more than half my life… After thousands of surgeries, the excitement and sense of responsibility of the first day still outweigh it. My father was a doctor, a neurologist too. I would always give the same response to those asking what I would be in elementary and secondary school: Neurosurgeon. When I started my neurosurgery residency at Haydarpaşa Numune Hospital in 1992, my childhood goal was fulfilled. Two points have always stood out from the others throughout my medical career: 1. Don’t harm anyone. 2. The most important relationship between the doctor and patient is the relationship of trust. In line with the principle of “first do no harm” in Turkish with “primum non nocere” in Latin, I have always preferred to perform secured surgeries under the microscope from smaller incisions. I didn’t perform any surgery that I wasn’t sure the patient would benefit from. So I’ve always been in a position to convince myself first of the need for surgery. Then I convince my patient. I kept in mind that the most important relationship between surgeon and patient is the relationship of trust. How can a person entrust his life to someone he saw 15 minutes ago without a relationship of trust? I cared about this relationship lasting post-surgery and even for life. I’ve had the first walks of my patients that I’ve operated in 28 years. Sometimes even after midnight many times… I’ve always cared about some patients’ feeling of their need to see their physician even at 03.00 o’clock midnight. I don’t mind giving all my patients my cell phone number. I would want my physician to be available at any time as needed. That’s what I do for my patients. In these lines, I felt the need to describe my view of medicine. Anyone who wonders anyway can reach my resume and my publications.

Education

Doctor of Medicine: Istanbul University Cerrahpaşa Faculty of Medicine (1987-1993)
Neurology Specialist: Osmangazi University Faculty of Medicine (1997-2001)
Stroke Fellow: University of Calgary, Canada (2008-2009)
Assistant Professor: Trakya University Faculty of Medicine (2001-2006)
Associate Professor: Trakya University Faculty of Medicine (2006-2010), Bezmialem Faculty of Medicine (2010-2012)
Professor: Bezmialem Faculty of Medicine (2012-2017), Memorial Hizmet Hospital (2017-2019, 2021-2023)
Interventional Neurologist: King Hamad University Hospital, Bahrain (2019-2021)
Consultant Neurologist: Salmaniya Medical Complex, Bahrain (2023-2024)

Between 2008-2009, I worked as a stroke fellow at the University of Calgary Stroke Program for 1 year.
During my tenure at Bezmialem Vakıf University, I received interventional neurology training from Prof. Dr. Ömer Göktekin.
2019-2021 I worked as an interventional neurologist at Arabian Gulf University and King Hamad University Hospital in Bahrain.
I worked as a consultant neurologist at Salmaniya Medical Complex in Bahrain between 2023-2024.

Medical Intrests 

• Stroke
• Interventional Norology
• Headache
• Demyelinating Diseases
• Dementia
• Movement Disorders
• Epilepsy

Education

Cumhuriyet University Faculty of Medicine, 2004
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine Residency, 2010
Karadeniz Technical University Faculty of Medicine Medical Oncology Residency, 2015

Experience

MD Andeson Cancer Center, USA, 2008
Sunnybrook Odette Cancer Center Breast Cancer Clinic, Canada, 2017
Moffit Cancer Center , USA 2022
Istanbul Haydarpaşa Training and Research Hospital Internal Medicine, 2010
İdil State Hospital Internal Medicine Clinic, 2011
Karadeniz Technical Universityniversitesi Faculty of Medicine, Medical Oncology Clinic, 2015
Istanbul Göztepe Training and Research Hospital, Medical Oncology Clinic, 2018
Yeniyüzyıl University Gaziosmanpaşa Hospital, Medical Oncology Clinic, 2020
Ataşehir Medicana Hospital, Medical Oncology Clinic, 2022

Scientific Membership

Turkish Medical Association (TTB)
Turkish Society of Medical Oncology (TTOD)
European Society for Medical Oncology (ESMO)
American Society of Medical Oncology (ASCO)

Medical Intrests

• Breast Cancer
• Lung Cancer
• Colon Cancer
• Stomach Cancer
• Rectal Cancer
• Ovarian Cancer
• Liver Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Kidney Cancer
• Larynx Cancer - Cancer of the Larynx
• Thyroid Cancer
• Head and Neck Cancers
• Gynaecological Cancers
• Pancreatic Cancer
• Oesophageal Cancer - Oesophageal Cancer
• Uterine Cancer
• Brain Cancers - Brain Tumours
• Soft Tissue Cancer - Sarcomas
• Prostate Cancer
• Bladder Cancer
• Bile Tract Cancer
• Testicular Cancer
• Cervical Cancer
• Mouth, Tongue, Lip Cancers
• Gastrointestinal System Cancers
• Bone Tumours
• Trachea and Bronchial Cancers
• Skin Cancers - Skin Cancers
• Skeletal System Tumours
• Gallbladder Cancer
• Mesothelioma

Education

GATA Faculty of Medicine, Doctor of Medicine Education, 1984, Ankara/Istanbul
GATA Faculty of Medicine, Neurology Residency, 1992, Ankara/Istanbul

Experience

GATA Neurology Department Specialization Student (1987-1992, Ankara/Turkey)
GATA Neurology Department Assistant Professor (1992-1995, Ankara/Turkey)
KüTahya Air Hospital Neurology Specialist and Chief Physician (1995-2003, Kütahya/Turkey)
Şişli Memorial Hospital Neurology Specialist (2004-2021, Istanbul/Turkey)

I completed my primary, secondary and high school education in Konya, my hometown, and my medical school and medical specialty education in Ankara GATA. I received flight medicine training and worked as a flight physician in the military and civilian sectors. I received beginner and advanced photography training and opened 4 photography exhibitions. I have made photography studies in 56 countries in Turkey and in 56 countries that I had the opportunity to visit.

Scientific Memberships

Turkish Medical Association
DGCA Health Board Membership